Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBENECID vs PRINCIPEN W/ PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.
FDA: Treatment of hyperuricemia associated with gout (prophylaxis and chronic management), adjunct to penicillin or cephalosporin therapy to elevate and prolong antibiotic levels.,Off-label: Prevention of nephropathy in patients with hyperuricemia, adjunct to antiviral agents (e.g., cidofovir) to reduce nephrotoxicity.
Respiratory tract infections,Urinary tract infections,Meningitis,Septicemia,Endocarditis,Gonorrhea (uncomplicated)
Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.
1.5-3 g IM q6h (20 mg/kg/day probenecid component).
Terminal elimination half-life is approximately 6-12 hours in adults with normal renal function; may be prolonged in renal impairment or older adults.
Ampicillin: 1-1.8 hours (prolonged to 4-6 hours with probenecid due to reduced renal clearance). Probenecid: 6-12 hours. Clinical context: extended half-life allows less frequent dosing.
Primarily hepatic via oxidation and glucuronidation; minor renal metabolism.
Ampicillin is metabolized by hydrolysis to penicilloic acid; probenecid undergoes hepatic metabolism via glucuronidation and oxidation.
Renal excretion of unchanged drug and metabolites; ~77% of dose recovered in urine within 48 hours (50% as glucuronide conjugates, 27% as unchanged probenecid); ~11% excreted in feces via biliary elimination.
Renal: ~60-80% of ampicillin excreted unchanged in urine via tubular secretion and glomerular filtration; probenecid reduces this to ~20-30%. Biliary/fecal: minor, <10%.
Approximately 75-95% bound to plasma albumin.
Ampicillin: 15-25% bound to albumin. Probenecid: 85-95% bound to albumin.
Apparent volume of distribution is about 9 L (approximately 0.13 L/kg in adults); indicates limited extravascular distribution, primarily confined to plasma and extracellular fluid.
Ampicillin: 0.3-0.4 L/kg (distributes well into extracellular fluid, low CNS penetration unless inflamed meninges).
Oral bioavailability is nearly complete (>90%) with peak plasma concentrations achieved within 2-4 hours.
Oral: 30-50% for ampicillin (enhanced by probenecid? probenecid does not significantly alter ampicillin absorption). Probenecid: nearly 100% oral.
GFR 10-50 m L/min: 250 mg once daily or 500 mg every 12-24 hours; GFR <10 m L/min: avoid use; anuria: contraindicated.
Cr Cl 30-50 m L/min: 1.5 g IM q8h; Cr Cl 10-29 m L/min: 1.5 g IM q12h; Cr Cl <10 m L/min: 1.5 g IM q24h.
No specific adjustment recommended; use caution in severe hepatic impairment.
No adjustment required for mild to moderate impairment. Severe impairment (Child-Pugh C): consider reducing dose by 25-50%.
For gout or hyperuricemia (children >2 years): 25 mg/kg/day (max 2 g/day) divided every 6-8 hours; as adjunct to penicillin/cephalosporin: 25 mg/kg/day (max 2 g/day) divided every 8 hours for infants >3 months and children; neonates: dose not established.
Children 2-12 years: 50 mg/kg/day IM in 4 divided doses (probenecid component 25 mg/kg/day). Maximum single dose 2 g.
Start at lowest dose (250 mg once daily) due to age-related renal impairment; monitor renal function regularly; avoid if GFR <30 m L/min.
Reduce dose based on renal function; avoid if Cr Cl <30 m L/min due to probenecid accumulation. Monitor for CNS toxicity.
None.
None.
Use with caution in patients with peptic ulcer disease.,May worsen acute gouty arthritis; prophylactic colchicine or NSAIDs recommended during initiation.,Risk of uric acid stone formation; ensure adequate hydration and alkalinize urine if needed.,Avoid use in patients with blood dyscrasias or bone marrow depression.,May interfere with urine glucose and ketone tests.
Hypersensitivity reactions including anaphylaxis,Severe cutaneous adverse reactions (SCARs),C. difficile-associated diarrhea,Renal impairment (dose adjustment for ampicillin),Sodium overload with high doses,Allergic cross-reactivity with cephalosporins
Hypersensitivity to probenecid or any component.,Severe renal impairment (Cr Cl <50 m L/min) or anuria.,History of uric acid kidney stones.,Concomitant use with methotrexate (increases methotrexate toxicity).,Use during acute gouty attack (unless already on therapy).
Hypersensitivity to penicillins or probenecid,History of cholestyramine or uricosuric agent hypersensitivity,Severe renal impairment (Cr Cl < 30 m L/min) for probenecid-containing products,Blood dyscrasias or uric acid calculi (probenecid)
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat) as they increase uric acid levels. Limit alcohol, especially beer and spirits, which increase uric acid. Maintain high fluid intake (water, citrus juices) to promote urine flow and prevent stones. Avoid cranberry juice as it may acidify urine.
Take with food or milk to reduce gastrointestinal upset. Avoid high-fat meals as they may delay absorption of ampicillin. Probenecid is not affected by food; however, maintain adequate hydration to prevent crystalluria.
Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known teratogenic effects. Second and third trimesters: No specific fetal risks documented; avoid near term due to potential for neonatal hyperbilirubinemia (displaces bilirubin from albumin).
FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratogenic effects. Second/third trimester: Use caution due to potential for altered fetal gut flora. Peripartum: Risk of kernicterus in neonates if maternal hyperbilirubinemia.
Probenecid is excreted into breast milk in low concentrations; M/P ratio not available. Consider benefits of breastfeeding versus potential risk of adverse effects in infant (e.g., rash, gastrointestinal effects). Use with caution.
Ampicillin excreted in breast milk in low levels (M/P ratio 0.02-0.1); probenecid probably excreted but data limited. Compatible with breastfeeding; monitor infant for diarrhea, rash, or candidiasis. Theoretical risk of kernicterus in jaundiced infants if probenecid displaces bilirubin.
No formal pharmacokinetic studies during pregnancy. Dose adjustment not routinely recommended, but consider decreased efficacy due to increased renal clearance in pregnancy. Monitor clinical response and adjust dose if needed.
Increased renal clearance in pregnancy may reduce ampicillin levels; consider higher doses or more frequent intervals for severe infections. Probenecid dose adjustment not typically required, but monitor for efficacy. Use standard doses for UTI unless resistant organisms suspected.
Probenecid inhibits renal tubular secretion of uric acid, increasing its excretion; used for chronic gout, not acute attacks. It also reduces renal excretion of penicillins and cephalosporins, so it is used to increase serum levels of these antibiotics. Ensure adequate hydration (at least 2-3 L daily) to prevent urate nephropathy. Avoid in patients with creatinine clearance <50 m L/min, history of uric acid stones, or acute gout attack. Alkalinization of urine (urine p H 6.5-7) reduces stone risk. Monitor serum uric acid, renal function, and CBC. Drug interactions: potentiates toxicity of methotrexate, NSAIDs, thiazides, salicylates (salicylates antagonize uricosuric effect).
Principen w/ Probenecid combines ampicillin, a broad-spectrum penicillin, with probenecid to prolong ampicillin serum levels by inhibiting renal tubular secretion. Use in penicillin-allergic patients is contraindicated. Probenecid may reduce excretion of other drugs (e.g., methotrexate, NSAIDs). Monitor renal function; probenecid is contraindicated in patients with uric acid kidney stones or blood dyscrasias. Administer with food if GI upset occurs. Synergistic with aminoglycosides but physically incompatible; do not mix in IV solutions.
Take probenecid with food or antacids to reduce GI upset.,Drink at least 8-10 glasses of water daily while on this medication.,Do not take aspirin or other salicylates; they can reduce the effect.,This drug may increase bleeding risk if you take blood thinners like warfarin.,Report any signs of allergic reaction, rash, or fever immediately.,Avoid alcohol as it increases uric acid levels.,Tell your doctor before taking other medications, especially antibiotics.,Do not use during an acute gout attack; wait until attack resolves.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Store at room temperature, away from moisture and heat.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course to prevent antibiotic resistance.,May cause diarrhea; contact your doctor if it is severe or contains blood.,Avoid alcohol while taking this medication.,Inform your doctor if you have kidney disease, gout, or a history of penicillin allergy.,Probenecid may increase effects of warfarin; monitor for bleeding.,Drink plenty of fluids to prevent kidney stones while on probenecid.
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBENECID vs PRINCIPEN W/ PROBENECID, answered by our medical review team.
PROBENECID is a Uricosuric that works by Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).. PRINCIPEN W/ PROBENECID is a Uricosuric that works by Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBENECID and PRINCIPEN W/ PROBENECID depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBENECID is: Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.. The standard adult dose of PRINCIPEN W/ PROBENECID is: 1.5-3 g IM q6h (20 mg/kg/day probenecid component).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBENECID and PRINCIPEN W/ PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBENECID is classified as Category A/B. Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known . PRINCIPEN W/ PROBENECID is classified as Category A/B. FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratoge. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.